ERBB2 and ovarian carcinoma: Chan et al investigated the cell killing ability of CIK cells against primary ovarian carcinoma cells with and without BsAbs and revealed that a CA125/Her2 BsAb significantly enhanced the cytotoxicity of CIK cells in primary ovarian cancer cells in a mouse model (17).